| Recruitment status | Terminated |
| Unique ID issued by UMIN | UMIN000004813 |
| Receipt No. | R000005728 |
| Official scientific title of the study | Risk and safety to stop antiplatelet (aspirin)to perform an initial diagnostic endoscopy |
| Date of disclosure of the study information | 2011/04/01 |
| Last modified on | 2017/06/08 (Ver. 3) |
| Basic information | ||
| Official scientific title of the study | Risk and safety to stop antiplatelet (aspirin)to perform an initial diagnostic endoscopy | |
| Title of the study (Brief title) | Risk and safety to stop aspirin to perform an endoscopy | |
| Region |
|
|
| Condition | |||
| Condition | Coronary artery disease patients not to be stopped aspirin to perform an initial diagnostic endoscopy. | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | Risk and safety to stop aspirin to perform an initial diagnostic endoscopy.The decision to reverse or to stop this therapy, risking an adverse ischemic event. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Phase II,III |
| Assessment | |
| Primary outcomes | bleeding rate to be performed the endoscopic procedures(biopsy) and adverse ischemic event rate to stop aspirin. |
| Key secondary outcomes | Efficacy and safety to Cilostazol |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Aspirin Discontinue for a short period of time (3days) before the endoscopic procedure. after that, Cilostazol uses 2days before the procedure(biopsy).
Endoscopic morning day only stop cilostazol. From next day,aspirin starts in the management. |
|
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | patients are used to aspirin in the management coronary artery disease and can not stop aspirin therapy before the endoscopic procedure(biopsy)(patients may be at too high of a risk to safely stop aspirin).
|
|||
| Key exclusion criteria | Malignancy, Zollinger-Ellison syndrome, pregnancy, a history of esophago-gastric surgery, continue bleeding from the GI tract, can not use the cilostazol, and can not take informed consent. | |||
| Target sample size | 50 | |||
| Research contact person | |
| Name of lead principal investigator | Yutaka Sasaki |
| Organization | Graduate School of Medical Sciences, Kumamoto University |
| Division name | Department of Gastroenterology and Hepatology |
| Address | 1-1-1 Honjo, Kumamoto City, Kumamoto 860-8556, Japan |
| TEL | 096-373-5150 |
| sakurai@s3.kcn-tv.ne.jp | |
| Public contact | |
| Name of contact person | kouichi Sakurai |
| Organization | Graduate School of Medical Sciences, Kumamoto University |
| Division name | Department of Gastroenterology and Hepatology |
| Address | 1-1-1 honjo, Kumamoto City, Kumamoto 860-8556, JAPAN |
| TEL | 096-373-5150(+81-96-373-5150) |
| Homepage URL | |
| sakurai@s3.kcn-tv.ne.jp | |
| Sponsor | |
| Institute | Graduate School of Medical Sciences, Kumamoto University |
| Institute | |
| Department | |
| Funding Source | |
| Organization | no |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Terminated | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005728 |